Contrary to the conclusion of a 2018 Taiwanese study, the authors of a large UK study said they found no evidence associating the use of metformin with a reduced risk of age-related macular degeneration (AMD) in patients requiring type-2 diabetes treatment.

The study of 173,689 type-2 diabetes patients was led by Dr Nicola Adderley, University of Birmingham, in partnership with the National Institute for Health Research (NIHR) Biomedical Research Centre, Moorfields Eye Hospital and University College London. Of the 3,111 patients who developed AMD, the adjusted hazard ratio was 1.02 in those prescribed metformin, compared to those prescribed other anti-diabetic medication only.